Browse the evidence

Tirzepatide produces significantly greater weight loss than semaglutide in adults with obesity or overweight, with the magnitude of loss increasing with higher doses (>10 mg) and longer treatment durations (>6 months).

If you are using semaglutide and not achieving your weight loss goals, switching to tirzepatide (particularly at doses above 10 mg and continuing for more than 6 months) is likely to result in significantly greater weight loss. The data supports tirzepatide as a more potent option for reducing body weight compared to semaglutide.

Weekly administration of semaglutide at 2.4 mg induces significant weight loss (mean 14.9%) and improves glycemic control (HbA1c < 7.0% in 57-74% of patients) in adults with obesity or type 2 diabetes, with effects proportional to dose and duration.

If you have obesity or type 2 diabetes, weekly semaglutide (2.4 mg for weight loss, 1-1.0 mg for diabetes) is a highly effective treatment that can lead to significant weight loss (up to 15%) and better blood sugar control. While nausea and vomiting are common side effects, they are usually mild and temporary, and weight loss often occurs regardless of whether you experience them. An oral version is also available if you prefer to avoid injections. Discuss this with your doctor to see if it's right for you.

Tirzepatide produces significantly greater weight loss than semaglutide in overweight and obese adults, with a standardized mean difference of 0.75 favoring tirzepatide.

If you are choosing between tirzepatide and semaglutide for weight loss, current direct comparative evidence suggests tirzepatide may lead to greater weight reduction. This benefit comes with a dual-hormone mechanism (GIP/GLP-1) and requires weekly injections. You should expect potential gastrointestinal side effects during dose increases, which are usually manageable. Combining the medication with diet and exercise will likely enhance results.

Tirzepatide significantly increases the odds of achieving clinically meaningful weight loss (≥10% body weight reduction) compared to semaglutide.

A key benefit of tirzepatide over semaglutide is the increased likelihood of losing 10% or more of your body weight, a threshold often associated with significant health improvements. This makes tirzepatide a potentially more effective option if your primary goal is substantial weight reduction. Discuss with your provider whether this higher efficacy profile aligns with your health goals.

Oral semaglutide (50 mg once daily) is effective for weight loss in non-diabetic obese/overweight adults, though generally less effective than the subcutaneous 2.4 mg formulation.

If you prefer not to use injections, oral semaglutide (50 mg daily) is a viable option for weight loss in non-diabetic adults with obesity. It produces significant weight loss (average 15%), though it requires daily adherence. It is generally considered less effective than the weekly injectable form, so discuss with your provider which form best fits your lifestyle and medical needs.

Subcutaneous semaglutide 2.4 mg once weekly produces 15–17% mean weight loss and offers cardioprotection in obesity treatment.

If you have obesity, subcutaneous semaglutide 2.4 mg once weekly is an approved treatment that can help you lose 15–17% of your body weight and may protect your heart. This is significantly more effective than lifestyle changes alone, which often fail to maintain weight loss long-term.

Tirzepatide, a dual GLP-1/GIP receptor agonist, achieves up to 22.5% mean weight loss in phase 3 obesity trials.

Tirzepatide is a dual-acting hormone medication (GLP-1/GIP) that can lead to up to 22.5% weight loss in clinical trials, surpassing single-agonist GLP-1 drugs. It is available for obesity management.

Oral semaglutide 50 mg once daily results in 17.4% weight loss in people with obesity without type 2 diabetes.

For those who prefer not to inject medication, oral semaglutide 50 mg once daily can achieve 17.4% weight loss in people with obesity without diabetes, comparable to the injectable version.

Resistance exercise training improves glycemic control and insulin sensitivity in older adults with type 2 diabetes or prediabetes, independent of changes in lean body mass.

If you have prediabetes or Type 2 Diabetes, adding resistance training 2-3 times a week can significantly improve your blood sugar control. Focus on progressive exercises at a moderate-to-high intensity (70-85% of your one-rep max). This works by improving how your muscles use insulin, not just by building muscle.

Omega-3 fatty acid supplementation (EPA/DHA) potentiates muscle protein synthesis and increases lean mass/strength in older adults, particularly when baseline protein intake is suboptimal.

Older adults aiming to build or maintain muscle should consider supplementing with 1.86g EPA and 1.50g DHA daily. This is most effective if your overall protein intake is not already maximized, as omega-3s help sensitize muscle to protein stimulation. Ensure you are getting adequate protein from food as well.

Ketogenic diets significantly improve glycemic control and reduce insulin requirements in patients with Type 2 Diabetes, allowing for medication discontinuation or reduction in a subset of patients.

If you have Type 2 Diabetes, a ketogenic diet (<20g carbs/day) can significantly lower your HbA1c and reduce your need for medication. However, you must work with your doctor to adjust your insulin or oral medications to avoid dangerous hypoglycemia. Do not stop medications abruptly without monitoring your blood glucose.

Older adults (65+ years) require higher protein intakes (1.2–1.4 g/kg/day) than the standard RDA (0.8 g/kg/day) to maintain lean body mass and stimulate muscle protein synthesis.

If you are over 65, aim for 1.2 to 1.4 grams of protein per kilogram of body weight every day. This is higher than the standard recommendation of 0.8 g/kg. This higher intake helps counteract the natural loss of muscle strength and mass associated with aging. Ensure you are also engaging in resistance exercise to maximize these benefits.

Whey protein isolate is superior to other protein sources for stimulating muscle protein synthesis in older adults due to its high leucine content.

For older adults, whey protein isolate is an excellent choice for stimulating muscle growth because it is rich in leucine, the key trigger for muscle synthesis. If you cannot consume dairy, combine plant proteins to ensure adequate leucine intake.

Bariatric surgery resolves Polycystic Ovary Syndrome (PCOS) symptoms, including menstrual irregularities and hirsutism, and improves fertility in obese women, largely through weight loss and hormonal normalization.

If you are obese and have PCOS, bariatric surgery can significantly improve your menstrual cycles, reduce excess hair growth, and increase your chances of conceiving. This is achieved through hormonal normalization and weight loss.

Survodutide, a dual glucagon/GLP-1 receptor agonist, produces dose-dependent reductions in HbA1c and bodyweight in people with type 2 diabetes, with doses ≥1.8 mg once weekly yielding greater bodyweight loss than semaglutide 1.0 mg.

For individuals with type 2 diabetes seeking significant weight loss and glucose control, dual GLP-1/GCGR agonists like survodutide offer superior bodyweight reduction compared to standard GLP-1 therapies like semaglutide, particularly at doses of 1.8 mg/week or higher. Expect gastrointestinal side effects, which can be managed by starting with lower doses and escalating slowly.

Once-weekly subcutaneous administration of GLP-1R/GIPR dual agonist tirzepatide (up to 15 mg/week) significantly reduces HbA1c and body weight in patients with type 2 diabetes, with efficacy exceeding current GLP-1RAs.

If you have type 2 diabetes and struggle with weight, ask your doctor about tirzepatide. It is a once-weekly injection that has been shown to lower blood sugar and reduce body weight more effectively than older GLP-1 drugs. While injections can be a barrier, oral options exist for other drugs in this class.

Combining the amylin analogue cagrilintide (4.5 mg/week) with semaglutide (2.4 mg/week) results in greater weight loss (15.4% reduction) than either agent alone in obese or overweight individuals.

For significant weight loss, combining cagrilintide and semaglutide has shown a 15.4% body weight reduction in 20 weeks. This combination therapy is an option for those who do not achieve sufficient weight loss with single-agent GLP-1 therapy.

Insufficient or fragmented sleep reduces skeletal muscle protein synthesis rates and promotes a catabolic hormonal environment (elevated cortisol, reduced testosterone/GH), leading to potential loss of lean mass and strength over time.

Prioritize 7-9 hours of sleep nightly to protect muscle mass. Sleep loss directly reduces your body's ability to build muscle (protein synthesis) and shifts hormones toward breaking it down (catabolism). If you are training hard, poor sleep undermines your gains more than you might think. Consistency in sleep duration is as important as consistency in training.

Regular physical exercise training significantly improves insulin sensitivity and reduces cardiovascular risk factors (including blood pressure, HbA1c, and lipid profiles) in subjects with insulin resistance, metabolic syndrome, or type 2 diabetes.

Engage in regular physical activity, prioritizing aerobic exercise for metabolic syndrome components. Aim for higher volumes (approaching 170 minutes/week) if possible, as duration appears to drive insulin sensitivity improvements more than intensity alone. Combine exercise with dietary changes for best weight maintenance results. Do not abandon exercise if scale weight changes are modest; the cardiovascular and metabolic benefits (lower BP, better insulin sensitivity) are significant even without major weight loss.

Weight loss significantly reduces the risk of postmenopausal breast cancer, with a dose-response relationship where greater weight loss leads to greater decreases in estrogen and increased sex hormone-binding globulin (SHBG).

If you are postmenopausal and overweight, losing even a small amount of weight (more than 5% of your body weight) can significantly lower your risk of breast cancer. This happens because losing fat reduces the amount of estrogen your body produces and increases the protein that binds up remaining estrogen, protecting your breast tissue. You don't need to reach an 'ideal' weight to see benefits; the act of losing weight itself changes your hormonal environment in a protective way.

GLP-1 receptor agonists (specifically Liraglutide 3.0mg and Semaglutide 2.4mg) significantly reduce the incidence of type 2 diabetes in obese individuals with prediabetes, often outperforming placebo and sometimes matching or exceeding lifestyle interventions.

If you are obese and have prediabetes, ask your doctor about GLP-1 medications like Semaglutide or Liraglutide. They are highly effective at preventing diabetes, often working better than diet and exercise alone because they help control appetite and blood sugar automatically.

Acute ingestion of 3 mg/kg caffeine significantly improves resistance exercise performance (velocity, power, repetitions), jumping height, and sprinting power in resistance-trained men, regardless of CYP1A2 genotype (AA vs. AC/CC).

Take 3 mg of caffeine per kg of body weight about an hour before your workout. This will likely improve your speed, power, and number of reps in resistance training, jumping, and sprinting. You do not need to worry about your CYP1A2 genotype (fast vs. slow metabolizer) as this dose works for everyone. Stick to this moderate dose; you don't need extreme amounts to see benefits.

Triple incretin agonists (GLP-1R/GIPR/GCGR) produce superior body weight reduction (up to 24.2%) compared to dual or mono-agonists, approaching the efficacy of bariatric surgery.

Retatrutide, a once-weekly injection targeting three gut hormone receptors, has shown remarkable weight loss results (up to 24% in trials). While side effects like nausea are common, they are often manageable by starting with a lower dose. This therapy represents a significant advancement over older GLP-1 drugs, offering efficacy closer to bariatric surgery without the surgical risks.

GLP-1/Glucagon dual agonists (e.g., mazdutide, survodutide) produce greater weight loss and triglyceride reduction compared to GLP-1 mono-agonists.

Dual agonists targeting GLP-1 and Glucagon receptors (like survodutide) have shown significant weight loss (up to 18.7%) and improved triglyceride levels in Phase 2 trials. These drugs leverage the fat-burning and energy-expenditure effects of glucagon while maintaining glucose control through GLP-1.